Ticker
$XFOR
1 catalyst touching XFOR in the last 60 days, newest first, each with the price move that followed.
- 72
X4 Pharma secures $80M term loan from K2 HealthVentures; $70M more available
X4 Pharmaceuticals closed a $150 million loan facility with K2 HealthVentures, immediately drawing $80 million and securing up to $70 million additional. The company repaid its prior Hercules debt and received proceeds for working capital, de-risking near-term liquidity while the loan is gated on achieving first commercial sales of mavorixafor (its main pipeline asset) and maintains significant covenant restrictions on operations.
XFOR ▲SEC 8-K · 8 Oct 2026, 21:23 UTC
Information only. AURA does not give buy or sell recommendations.